Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Remission of TP53-Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen Receptor T (VCAR33).
Journal: JCO precision oncology
Published: October 23, 2025
CRISPR-Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial.
Journal: Nature medicine
Published: August 01, 2025
Peripheral Blood Tumor Associated Cell-Free DNA Testing as a Predictor for Relapse Postallogeneic Stem Cell Transplant for Acute Myelogenous Leukemia.
Journal: Transplantation and cellular therapy
Published: May 09, 2025
Prospective, Randomized, Comparative Study of Myeloablative Fludarabine/Busulfan and Fludarabine/Busulfan/Total Body Irradiation Conditioning in Myeloid Diseases.
Journal: Cancers
Published: March 07, 2025
cfDNA Chimerism and Somatic Mutation Testing in Early Prediction of Relapse After Allogeneic Stem Cell Transplantation for Myeloid Malignancies.
Journal: Cancers
Published: December 17, 2024
Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in de novo large B-cell lymphoma and transformed low-grade B-cell lymphoma.
Journal: Haematologica
Published: November 26, 2023
An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma.
Journal: Nature medicine
Published: July 07, 2023
Chronic myeloid leukemia stem cells require cell-autonomous pleiotrophin signaling.
Journal: The Journal of clinical investigation
Published: March 25, 2019
Last Updated: 09/26/2026